How Many Lymphadenectomies Does It Take to Cure One Patient?

European Urology

Volumn 53, Issue 1, 2008, Pages 13-15

  Klein, Eric A ^a   Kattan, Michael ^b   Stephenson, Andrew ^a   Vickers, Andrew ^c  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CALCULATION; CANCER MORTALITY; CANCER SURVIVAL; EDITORIAL; EVALUATION; HUMAN; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROSTATECTOMY; RISK BENEFIT ANALYSIS; UROGENITAL TRACT CANCER;

HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; PELVIS; PROSTATIC NEOPLASMS;

EID: 36448946507     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.09.017     Document Type: Editorial

References (11)

1. Bader P., Burkhard F.C., Markwalder R., and Studer U.E. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?. J Urol 169 (2003) 849-854
2. Allaf M.E., Palapattu G.S., Trock B.J., Carter H.B., and Walsh P.C. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 172 (2004) 1840-1844
3. Daneshmand S., Quek M.L., Stein J.P., et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 172 (2004) 2252-2255
4. Berglund R.K., Sadetsky N., DuChane J., Carroll P.R., and Klein E.A. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE. J Urol 177 (2007) 526-529
5. DiMarco D.S., Zincke H., Sebo T.J., Slezak J., Bergstralh E.J., and Blute M.L. The extent of lymphadenectomy for pTXN0 prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173 (2005) 1121-1125
6. Bhatta-Dhar N., Reuther A.M., Zippe C., and Klein E.A. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology 63 (2004) 528-531
7. Miyake H., Hara I., Kurahashi T., Inoue T.A., Eto H., and Fujisawa M. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res 13 (2007) 1192-1197
8. Mattei A., Fuechsel F.G., Bhatta Dhar N., et al. The template of primary landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53 (2008) 118-125
9. Masterson T.A., Bianco Jr. F.J., Vickers A.J., et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 175 (2006) 1320-1324
10. Touijer K., Rabbani F., Otero J.R., et al. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol 178 (2007) 120-124
11. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479